AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25782469 — intervention group
Group type: COMPARATOR
Intervention: 2.25 g SMO.IR matching placebo and placebo alcohol preparation
Number of subjects: 24
Study 23453866 — intervention group
Group type: EXPERIMENTAL
Intervention: AGE-S (250 mg aged garlic extract, 100 μg vitamin B12, 300 μg folic acid, 12.5 mg vitamin B6, 100 mg L-arginine)
Number of subjects: 60
Study 23453866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 22053315 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Watchers
Number of subjects: 740
Study 22053315 — intervention group
Group type: EXPERIMENTAL
Intervention: Slimming World
Number of subjects: 740
Study 22053315 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosemary Conley
Number of subjects: 740
Study 22053315 — intervention group
Group type: EXPERIMENTAL
Intervention: Group based, dietetics led programme
Number of subjects: 740
Study 22053315 — intervention group
Group type: EXPERIMENTAL
Intervention: General practice one to one counselling
Number of subjects: 740
Study 22053315 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy led one to one counselling
Number of subjects: 740
Study 22053315 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice of any of the six programmes
Number of subjects: 740
Study 22053315 — intervention group
Group type: COMPARATOR
Intervention: Comparator group (minimal intervention control)
Number of subjects: 740
Study 19640315 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic methylprednisolone injections
Number of subjects: 70
Study 19640315 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 70
Study 17432284 — intervention group
Group type: EXPERIMENTAL
Intervention: Psicoeducative Program
Number of subjects: 177
Study 15152882 — intervention group
Group type: EXPERIMENTAL
Intervention: 50-minute telephone counseling with 2 follow-up calls
Number of subjects: 632
Study 15152882 — intervention group
Group type: COMPARATOR
Intervention: Print only control (pamphlet/booklet)
Number of subjects: 632
Study 15152882 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 calls
Number of subjects: 632
Study 15152882 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 calls
Number of subjects: 632
Study 11321635 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced mood via auditory, visual, and imaginal channels
Number of subjects: 118
Study 11321635 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reports of induced mood
Number of subjects: 118
Study 8583171 — intervention group
Group type: EXPERIMENTAL
Intervention: BROM II device for measuring lumbar mobility
Number of subjects: 47
Study 2526031 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol (200 mg three times a day)
Number of subjects: 20
Study 2526031 — intervention group
Group type: COMPARATOR
Intervention: High-dose medroxyprogesterone acetate (100 mg a day)
Number of subjects: 20
Study 2526031 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol and high-dose MPA
Number of subjects: 20
Study 925164 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational State Directed Imagery (RSDI)
Number of subjects: 0
Study 925164 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational (cognitive) restructuring treatment
Number of subjects: 0
Study 925164 — intervention group
Group type: COMPARATOR
Intervention: Placebo condition
Number of subjects: 0
Study 925164 — intervention group
Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 0
Study 31101403 — intervention group
Group type: EXPERIMENTAL
Intervention: Bexagliflozin, 20mg, daily for 24 weeks
Number of subjects: 312
Study 31101403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study 28276521 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated fatty acids (SFA)
Number of subjects: 0
Study 28276521 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsaturated fat
Number of subjects: 0
Study 28276521 — intervention group
Group type: EXPERIMENTAL
Intervention: SFA with fish oil
Number of subjects: 0
Study 28276521 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 26045359 — intervention group
Group type: EXPERIMENTAL
Intervention: Stribild(®) (EVG/COBI/FTC/TDF)
Number of subjects: 0
Study 26045359 — intervention group
Group type: COMPARATOR
Intervention: NNRTI with FTC/TDF (control group)
Number of subjects: 0
Study 25139785 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 153
Study 25139785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 22422736 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-drug chemotherapy (including doxorubicin) with or without lung radiation
Number of subjects: 417
Study 22422736 — intervention group
Group type: COMPARATOR
Intervention: 2-drug chemotherapy (dactinomycin and vincristine)
Number of subjects: 417
Study 22422736 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-only nodules with lung radiation
Number of subjects: 417
Study 22422736 — intervention group
Group type: COMPARATOR
Intervention: CT-only nodules without lung radiation
Number of subjects: 417
Study 18603457 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabinoid (delta‐9‐tetrahydrocannabinol (THC) and cannabidiol mixture) as an oromucosal spray
Number of subjects: 18
Study 17931519 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-port laparoscopic cholecystectomy
Number of subjects: 75
Study 17931519 — intervention group
Group type: COMPARATOR
Intervention: 4-port laparoscopic cholecystectomy
Number of subjects: 75
Study 16299295 — intervention group
Group type: EXPERIMENTAL
Intervention: MSP3-LSP vaccine with Montanide ISA 720
Number of subjects: 35
Study 16299295 — intervention group
Group type: EXPERIMENTAL
Intervention: MSP3-LSP vaccine with aluminum hydroxide
Number of subjects: 35
Study 16299295 — intervention group
Group type: EXPERIMENTAL
Intervention: MSP3-LSP vaccine
Number of subjects: 35
Study 12435326 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological therapies for OA
Number of subjects: 0
Study 12435326 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochrane systematic reviews of OA therapies
Number of subjects: 0
Study 9790423 — intervention group
Group type: EXPERIMENTAL
Intervention: Benznidazole at a dose of 5 mg/kg/day for 60 days
Number of subjects: 0
Study 9790423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9790423 — intervention group
Group type: EXPERIMENTAL
Intervention: Benznidazole
Number of subjects: 0
Study 8828629 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation with marine oils
Number of subjects: 0
Study 8828629 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation with blackcurrant oils
Number of subjects: 0
Study 8828629 — intervention group
Group type: COMPARATOR
Intervention: Good compliance with dietary regimen
Number of subjects: 0
Study 8828629 — intervention group
Group type: COMPARATOR
Intervention: Healthy control population
Number of subjects: 0
Study 1924079 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (4 micrograms/kg/min)
Number of subjects: 5
Study 7199836 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg of morphine epidurally
Number of subjects: 174
Study 7199836 — intervention group
Group type: COMPARATOR
Intervention: 0.1 mg/kg of morphine intramuscularly
Number of subjects: 174
Study 7199836 — intervention group
Group type: COMPARATOR
Intervention: saline epidurally
Number of subjects: 174
Study 30717684 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate injection
Number of subjects: 113
Study 30717684 — intervention group
Group type: COMPARATOR
Intervention: Sclerotherapy
Number of subjects: 113
Study 28651804 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin 1.5mg/m2 by 24‐hour IV infusion
Number of subjects: 232
Study 28651804 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine 1g/m2 by 20‐120‐minute IV infusion once every three weeks
Number of subjects: 232
Study 27523954 — intervention group
Group type: COMPARATOR
Intervention: Target temperature management (TTM) at 36°C
Number of subjects: 163
Study 27523954 — intervention group
Group type: COMPARATOR
Intervention: Target temperature management (TTM) at 33°C
Number of subjects: 163
Study 27523954 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombomodulin at 24h
Number of subjects: 163
Study 27523954 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombomodulin at 48h
Number of subjects: 163
Study 27523954 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 baseline levels
Number of subjects: 163
Study 27523954 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombomodulin increase from baseline to 48h
Number of subjects: 163
Study 27523954 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombomodulin increase from baseline to 72h
Number of subjects: 163
Study 25015203 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachytherapy boost (10 Gy in 2 fractions)
Number of subjects: 224
Study 25015203 — intervention group
Group type: COMPARATOR
Intervention: Long-course preoperative CRT (50.4 Gy in 28 fractions, per oral tegafur-uracil and L-leucovorin)
Number of subjects: 224
Study 20865425 — intervention group
Group type: EXPERIMENTAL
Intervention: Short intense local exercise (single‐legged toe lifting)
Number of subjects: 18
Study 20865425 — intervention group
Group type: COMPARATOR
Intervention: Euglycemic hyperinsulinemic clamp
Number of subjects: 18
Study 20865425 — intervention group
Group type: EXPERIMENTAL
Intervention: Before exercise
Number of subjects: 18
Study 20865425 — intervention group
Group type: EXPERIMENTAL
Intervention: After exercise
Number of subjects: 18
Study 19280592 — intervention group
Group type: EXPERIMENTAL
Intervention: 90Y-DOTA-Tyr3-octreotide (TOC)
Number of subjects: 24
Study 17572574 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical drainage on one side of the face
Number of subjects: 50
Study 17572574 — intervention group
Group type: COMPARATOR
Intervention: No surgical drainage (control side)
Number of subjects: 50
Study 15142211 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice A (RDA=85, REA=3.4)
Number of subjects: 0
Study 15142211 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice B (RDA=189, REA=2.0)
Number of subjects: 0
Study 15142211 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice C (RDA=132, REA=42.7)
Number of subjects: 0
Study 15142211 — intervention group
Group type: COMPARATOR
Intervention: Comparison between dentifrice C and dentifrices A and B
Number of subjects: 0
Study 11447952 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg/kg ketamine + 0.1 mg/kg diazepam
Number of subjects: 25
Study 11447952 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg ketamine + 0.1 mg/kg diazepam
Number of subjects: 25
Study 9727815 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrice weekly buprenorphine maintenance in primary care clinic
Number of subjects: 46
Study 9727815 — intervention group
Group type: COMPARATOR
Intervention: Traditional drug treatment program
Number of subjects: 46
Study 7498559 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic cyclosporine (CSA)
Number of subjects: 43
Study 7498559 — intervention group
Group type: COMPARATOR
Intervention: No CSA
Number of subjects: 43
Study 2683836 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP) 4 puffs of 50 micrograms b.i.d.
Number of subjects: 31
Study 2683836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 1114148 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (predominantly β‐2 stimulant)
Number of subjects: 9
Study 1114148 — intervention group
Group type: COMPARATOR
Intervention: Practolol (predominantly β‐1 blocking agent) with Salbutamol
Number of subjects: 9
Study 31630236 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankylosing spondylitis (AS) patients
Number of subjects: 3763
Study 31630236 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-AS subjects)
Number of subjects: 3763
Study 31715435 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blocker therapy
Number of subjects: 14671
Study 31715435 — intervention group
Group type: COMPARATOR
Intervention: No β-blocker therapy
Number of subjects: 14671
Study 28629468 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary glucose testing during antenatal care, followed by nutritional counselling and follow-up.
Number of subjects: 20
Study 28629468 — intervention group
Group type: COMPARATOR
Intervention: Standard practice for screening and initial management of GDM.
Number of subjects: 20
Study 26138425 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained inflation with 30 cmH2O
Number of subjects: 150
Study 26138425 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained inflation with 35 cmH2O
Number of subjects: 150
Study 26138425 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained inflation with varying pressures (P1, P2, P3, P4)
Number of subjects: 150
Study 26138425 — intervention group
Group type: COMPARATOR
Intervention: Control group (P0)
Number of subjects: 150
Study 24080100 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal treatment (scaling and root planing for a minimum of two 90-minute sessions, plus antibacterial mouth rinse for at least 32 days)
Number of subjects: 600
Study 24080100 — intervention group
Group type: COMPARATOR
Intervention: Control group (received periodontal treatment after 6 months)
Number of subjects: 600
Study 24080100 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal treatment
Number of subjects: 600
Study 20847112 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser scanning confocal microscopy
Number of subjects: 15
Study 20847112 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea tree oil treatment
Number of subjects: 15
Study 20847112 — intervention group
Group type: COMPARATOR
Intervention: Control group (8 age- and sex-matched control subjects)
Number of subjects: 15
Study 18374327 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10-80 mg/day)
Number of subjects: 102
Study 18374327 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 102
Study 18374327 — intervention group
Group type: COMPARATOR
Intervention: Control (age and gender-matched blood donors)
Number of subjects: 102
Study 16595275 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intention instructions
Number of subjects: 535
Study 16595275 — intervention group
Group type: COMPARATOR
Intervention: No implementation intention instructions (Control)
Number of subjects: 535
Study 12559540 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary spastic angina (CSA)
Number of subjects: 145
Study 12559540 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable effort angina (SEA)
Number of subjects: 145
Study 12559540 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 145
Study 12559540 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable effort angina (SEA) with small, dense LDL
Number of subjects: 145
Study 12559540 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary spastic angina (CSA) with small, dense LDL
Number of subjects: 145
Study 10698242 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group received educational brochures, telephone calls from senior volunteers, and computerized immunization tracking.
Number of subjects: 0
Study 10698242 — intervention group
Group type: COMPARATOR
Intervention: Control group, details not specified.
Number of subjects: 0
Study 10698242 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group, details not specified.
Number of subjects: 0
Study 9070556 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation
Number of subjects: 141
Study 9070556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 7828454 — intervention group
Group type: EXPERIMENTAL
Intervention: Methionyl growth hormone (0.3 mg/kg/week) administered daily
Number of subjects: 20
Study 7828454 — intervention group
Group type: COMPARATOR
Intervention: Methionyl growth hormone (0.3 mg/kg/week) administered 3 times per week (TIW)
Number of subjects: 20
Study 3513581 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral progesterone (4 capsules of 100 mg each)
Number of subjects: 57
Study 3513581 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 capsules)
Number of subjects: 57
Study 3513581 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral progesterone
Number of subjects: 57
Study 29894513 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity aerobic exercise (High-AEX)
Number of subjects: 22
Study 29894513 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity aerobic exercise (Mod-AEX)
Number of subjects: 22
Study 27254811 — intervention group
Group type: EXPERIMENTAL
Intervention: LoTor group (spherical orthokeratology lenses)
Number of subjects: 33
Study 27254811 — intervention group
Group type: EXPERIMENTAL
Intervention: HiTor group I (spherical orthokeratology lenses with conventional fitting)
Number of subjects: 33
Study 27254811 — intervention group
Group type: EXPERIMENTAL
Intervention: HiTor group II (spherical orthokeratology lenses with deeper sagittal height)
Number of subjects: 33
Study 27254811 — intervention group
Group type: COMPARATOR
Intervention: Comparison between LoTor group and HiTor group I
Number of subjects: 33
Study 27254811 — intervention group
Group type: COMPARATOR
Intervention: Comparison between HiTor group I and II
Number of subjects: 33
Study 27254811 — intervention group
Group type: COMPARATOR
Intervention: LoTor and HiTor group I combined
Number of subjects: 33
Study 25109375 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based telemonitoring (AllergyMonitor™)
Number of subjects: 63
Study 25109375 — intervention group
Group type: COMPARATOR
Intervention: Usual care (controls)
Number of subjects: 63
Study 22954616 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 26576 (450 mg BID)
Number of subjects: 54
Study 22954616 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 26576 (400 mg BID)
Number of subjects: 54
Study 22954616 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 26576
Number of subjects: 54
Study 22954616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 20195651 — intervention group
Group type: EXPERIMENTAL
Intervention: Bracing treatment for idiopathic scoliosis
Number of subjects: 4
Study 20195651 — intervention group
Group type: COMPARATOR
Intervention: Control arm (existing treatment)
Number of subjects: 4
Study 17934033 — intervention group
Group type: EXPERIMENTAL
Intervention: Canadian Quality Circle (CQC) educational intervention
Number of subjects: 52
Study 17934033 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 52
Study 15625582 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous breathing
Number of subjects: 16
Study 15625582 — intervention group
Group type: COMPARATOR
Intervention: Inspiratory pressure support
Number of subjects: 16
Study 11908492 — intervention group
Group type: EXPERIMENTAL
Intervention: E‐100 (estradiol, 100 microg/day)
Number of subjects: 160
Study 11908492 — intervention group
Group type: EXPERIMENTAL
Intervention: E‐50 (estradiol, 50 microg/day)
Number of subjects: 160
Study 11908492 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P‐100, placebo to E‐100)
Number of subjects: 160
Study 11908492 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P‐50, placebo to E‐50)
Number of subjects: 160
Study 10461109 — intervention group
Group type: COMPARATOR
Intervention: Tamm‐Horsfall protein excretion in pure uric acid stone formers
Number of subjects: 20
Study 10461109 — intervention group
Group type: EXPERIMENTAL
Intervention: Uric acid excretion in pure uric acid stone formers (group I)
Number of subjects: 20
Study 10461109 — intervention group
Group type: EXPERIMENTAL
Intervention: Uric acid excretion in mixed stone formers (group II)
Number of subjects: 20
Study 10461109 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium excretion in mixed stone formers (group II)
Number of subjects: 20
Study 10461109 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate excretion in both groups (I and II)
Number of subjects: 20
Study 8903836 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) 3 IU m‐2 daily
Number of subjects: 8
Study 8903836 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) 6 IU m‐2 daily
Number of subjects: 8
Study 8903836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2784831 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured teaching with a written guide
Number of subjects: 60
Study 2784831 — intervention group
Group type: COMPARATOR
Intervention: Unstructured method of education
Number of subjects: 60
Study 29732483 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO-SMART application
Number of subjects: 101
Study 28800725 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational prototype thermal compression device (full device group)
Number of subjects: 36
Study 28800725 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative forced air warming (FAW)
Number of subjects: 36
Study 28800725 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational prototype thermal compression device (single heating area)
Number of subjects: 36
Study 26151676 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate 1,000 mg plus prednisone/prednisolone 5 mg twice daily
Number of subjects: 350
Study 26151676 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus prednisone/prednisolone 5 mg twice daily
Number of subjects: 350
Study 24477726 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided IAI
Number of subjects: 71
Study 24477726 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy-guided IAI
Number of subjects: 71
Study 21948888 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 26
Study 21948888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 19917838 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with docetaxel, cisplatin, and fluorouracil (TPF)
Number of subjects: 265
Study 19917838 — intervention group
Group type: COMPARATOR
Intervention: Induction chemotherapy with cisplatin and fluorouracil (PF)
Number of subjects: 265
Study 16825692 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg yolk folate
Number of subjects: 13
Study 16825692 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinach folate
Number of subjects: 13
Study 16825692 — intervention group
Group type: EXPERIMENTAL
Intervention: Yeast folate
Number of subjects: 13